Your browser is no longer supported. Please, upgrade your browser.
OSMT Osmotica Pharmaceuticals plc weekly Stock Chart
Osmotica Pharmaceuticals plc
Index- P/E- EPS (ttm)-7.08 Insider Own0.30% Shs Outstand52.79M Perf Week5.26%
Market Cap190.04M Forward P/E- EPS next Y-1.04 Insider Trans- Shs Float7.65M Perf Month16.88%
Income-241.70M PEG- EPS next Q-0.23 Inst Own46.10% Short Float2.93% Perf Quarter9.42%
Sales246.70M P/S0.77 EPS this Y-151.70% Inst Trans-8.62% Short Ratio2.15 Perf Half Y-43.57%
Book/sh4.91 P/B0.73 EPS next Y38.80% ROA-31.50% Target Price8.50 Perf Year-
Cash/sh1.21 P/C2.98 EPS next 5Y- ROE-94.40% 52W Range2.20 - 9.90 Perf YTD-53.55%
Dividend- P/FCF6.46 EPS past 5Y- ROI-13.60% 52W High-63.18% Beta-
Dividend %- Quick Ratio1.50 Sales past 5Y- Gross Margin47.40% 52W Low65.68% ATR0.27
Employees466 Current Ratio1.80 Sales Q/Q-56.30% Oper. Margin-99.50% RSI (14)62.22 Volatility7.81% 8.51%
OptionableNo Debt/Eq1.04 EPS Q/Q- Profit Margin-98.00% Rel Volume2.28 Prev Close3.60
ShortableYes LT Debt/Eq1.04 EarningsAug 08 AMC Payout- Avg Volume104.40K Price3.64
Recom1.50 SMA2013.52% SMA5011.72% SMA200-27.31% Volume109,768 Change1.25%
Jun-11-19Initiated Barclays Overweight $11
Nov-12-18Initiated Wells Fargo Outperform
Nov-12-18Initiated RBC Capital Mkts Outperform $17
Nov-12-18Initiated Jefferies Buy $21
Sep-18-19 06:50AM  Vertical Pharmaceuticals LLC, an Osmotica company, Announces Presentation of Phase III RVL-1201 Clinical Trial Data in Patients with Acquired Blepharoptosis (droopy eyelid) GlobeNewswire
Sep-17-19 06:50AM  Vertical Pharmaceuticals, LLC, an Osmotica Company, Announces Submission of New Drug Application for RVL-1201 GlobeNewswire
Sep-04-19 06:50AM  Osmotica Pharmaceuticals plc Announces Results of Extraordinary General Meeting PR Newswire
Aug-28-19 04:30PM  Osmotica Pharmaceuticals plc to Present at 2019 Wells Fargo Healthcare Conference GlobeNewswire
Aug-22-19 01:06PM  Is Osmotica Pharmaceuticals (NASDAQ:OSMT) Using Debt Sensibly? Simply Wall St.
Aug-08-19 04:05PM  Osmotica Pharmaceuticals plc Reports Second Quarter 2019 Results GlobeNewswire
Aug-01-19 04:30PM  Osmotica Pharmaceuticals plc to Provide Second Quarter 2019 Business and Financial Update on August 8, 2019 GlobeNewswire
Jul-02-19 09:03PM  Shareholder Rights Law Firm Johnson Fistel Launches Investigations PR Newswire
May-30-19 04:30PM  Osmotica Pharmaceuticals plc to Present at Jefferies 2019 Global Healthcare Conference GlobeNewswire
May-23-19 12:05PM  Breakeven On The Horizon For Osmotica Pharmaceuticals plc (NASDAQ:OSMT) Simply Wall St. -8.46%
May-14-19 04:30PM  Osmotica Pharmaceuticals plc to Present at 2019 RBC Capital Markets Global Healthcare Conference GlobeNewswire -7.42%
May-09-19 04:01PM  Osmotica Pharmaceuticals plc Reports First Quarter 2019 Financial Results and Highlights Pipeline and Business Progress GlobeNewswire -5.14%
May-07-19 08:20AM  The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex Benzinga
May-06-19 04:30PM  Osmotica Pharmaceuticals plc Announces Positive Topline Results of Phase III Clinical Trials of RVL-1201 (RVL) for Acquired Blepharoptosis (ptosis or droopy eyelid) GlobeNewswire
May-02-19 05:00PM  Osmotica Pharmaceuticals plc to Provide First Quarter 2019 Business and Financial Update on May 9, 2019 GlobeNewswire
Apr-12-19 12:45PM  Robbins Arroyo LLP is Investigating the Officers and Directors of Osmotica Pharmaceuticals plc (OSMT) on Behalf of Shareholders Business Wire
Apr-11-19 12:05PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Osmotica Pharmaceuticals plc Investors Business Wire
Apr-08-19 03:06PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Osmotica Pharmaceuticals plc Investors (OSMT) Business Wire
Apr-02-19 04:41PM  Lifshitz & Miller LLP Announces Investigation of Amyris, Inc., iRhythm Technologies, Inc., Orion Group Holdings, Inc., Osmotica Pharmaceuticals plc, Quantenna Communications, Inc., WABCO Holdings, Inc. and Zafgen, Inc. PR Newswire +5.19%
02:21PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Osmotica Pharmaceuticals plc Investors (OSMT) Business Wire
Mar-29-19 02:17PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Osmotica Pharmaceuticals plc Investors Business Wire -9.89%
07:42AM  The Daily Biotech Pulse: Safety Board Clears Eisai's Alzheimer's Study, Positive Trial Results For Galapagos-Gilead Benzinga
Mar-28-19 11:54AM  SHAREHOLDER ALERT: Investigation of Osmotica Announced by Holzer & Holzer, LLC Business Wire -40.73%
Mar-27-19 04:05PM  Osmotica Pharmaceuticals plc Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress GlobeNewswire
Mar-13-19 07:07PM  Health Care Stocks Are Big Winners for an Aging Population
Dec-27-18 07:00AM  Osmotica Pharmaceuticals Appoints Seasoned Financial Executive Gregory Cowan to Board of Directors and Audit Committee GlobeNewswire -10.01%
Dec-03-18 04:30PM  Osmotica Pharmaceuticals to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference GlobeNewswire +12.06%
Nov-08-18 04:01PM  Osmotica Pharmaceuticals plc Reports Third Quarter 2018 Results GlobeNewswire
Nov-05-18 07:00AM  Osmotica Pharmaceuticals plc to Discuss Third Quarter 2018 Financial Results on November 8, 2018 GlobeNewswire
Oct-18-18 02:51PM  [$$] Osmotica Pharmaceuticals Shares Rise in Public Debut The Wall Street Journal
Oct-11-18 12:27PM  Osmotica's IPO: What You Need To Know Benzinga
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms. It also provides women's health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201 for treating Blepharoptos. In addition, the company's non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; Hydromorphone ER for treating; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate to treat hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex ANDAs and other ANDAs for various treatments. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.